--- title: "Thermo Fisher Scientific focuses on digital clinical and spends $8.875 billion in cash to acquire Clario" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/263277134.md" description: "Thermo Fisher Scientific acquired clinical trial data management company Clario Holdings for $8.875 billion in cash, expecting the transaction to enhance adjusted earnings per share by $0.45 in the first year post-closing and achieve approximately $175 million in adjusted operating profit synergies by the fifth year. This acquisition will strengthen Thermo Fisher Scientific's digital clinical evidence capabilities, with completion anticipated by mid-2026. In addition to the initial cash payment, Thermo Fisher Scientific will also pay up to $400 million in contingent consideration based on Clario's performance" datetime: "2025-10-29T11:34:02.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/263277134.md) - [en](https://longbridge.com/en/news/263277134.md) - [zh-HK](https://longbridge.com/zh-HK/news/263277134.md) --- > 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/263277134.md) | [English](https://longbridge.com/en/news/263277134.md) # Thermo Fisher Scientific focuses on digital clinical and spends $8.875 billion in cash to acquire Clario According to the Zhitong Finance APP, Thermo Fisher Scientific (TMO.US), a leader in life science tools and in vitro diagnostics in the United States, has confirmed that it has reached an acquisition agreement to acquire clinical trial data management company Clario Holdings for $8.875 billion in cash to be paid at closing from a shareholder group led by Astorg, Nordic Capital, Novo Holding, and Cinven. For Thermo Fisher, swallowing Clario will further strengthen its "digital clinical evidence" business capabilities. This transaction has immediate financial appeal in terms of enhancing profit margins and adjusted EPS, and bets on the long-term trend of FDA-guided DHT/DCT (Digital Health Technologies/Decentralized Trials). This major acquisition is expected to be completed by mid-2026, subject to customary closing conditions and formal approval from U.S. regulators. After the acquisition is completed, Clario will be integrated into Thermo Fisher's laboratory products and biopharmaceutical services business unit. According to a recent acquisition statement, in addition to the initial cash purchase price at closing, Thermo Fisher has agreed to pay $125 million in January 2027 and up to $400 million in contingent consideration based on the business's specific performance in 2026 and 2027. Public information shows that Clario integrates clinical trial endpoint data from endpoint detection/diagnostic devices, trial centers, and patients, enabling large clients in the pharmaceutical and biotechnology sectors to digitally collect, manage, and analyze clinical trial evidence at every stage of drug development. Over the past decade, the company's platform has supported approximately 70% of FDA drug approval processes. For the full year of 2025, this business is expected to generate approximately $1.25 billion in revenue. Under Thermo Fisher's ownership, this business is expected to achieve high unit-level growth. Marc N. Casper, Chairman, President, and CEO of Thermo Fisher, stated: "Clario is strategically aligned with us, enabling faster and more insightful drug development processes through differentiated technology and data intelligence solutions." This acquisition is expected to have a positive accretive effect on Thermo Fisher's adjusted operating profit margin in the first year after closing and to increase adjusted earnings per share by $0.45 in the first year after closing. The company expects to achieve approximately $175 million in adjusted operating profit after synergies in the fifth year following the completion of the acquisition. Analysts have stated that Thermo Fisher's acquisition of Clario further strengthens its "digital clinical evidence" capabilities after its acquisition of PPD (CRO): integrating eCOA, medical imaging, ECG/breathing, safety monitoring, wearable and site data into its own system, thereby connecting and digitizing the evidence chain from drug development to clinical trials to registration to commercialization, thus achieving higher customer stickiness, cross-selling, and sustainable growth, aiming to fully embed a "regulatory-grade clinical endpoint data platform" into its vast biopharmaceutical customer ecosystem Under the clear push from the FDA for DHT/DCT, eCOA/imaging/wearables to become the "new normal" in clinical settings, this acquisition by Thermo Fisher Scientific can be said to embody threefold value: cutting-edge strategic positioning, financial enhancement, and synergy within the medical ecosystem ### 相關股票 - [Thermo Fisher Scentific (TMO.US)](https://longbridge.com/zh-HK/quote/TMO.US.md) ## 相關資訊與研究 - [Thermo Fisher Scientific Launches Integrated Platform to Accelerate Biologics Development](https://longbridge.com/zh-HK/news/281367537.md) - [Here's How Much $1000 Invested In Thermo Fisher Scientific 15 Years Ago Would Be Worth Today](https://longbridge.com/zh-HK/news/269880072.md) - [Lindsay (LNN) Q1 Earnings Report Preview: What To Look For](https://longbridge.com/zh-HK/news/281292775.md) - [Motor racing-Sainz urges FIA to act after Bearman's Suzuka crash](https://longbridge.com/zh-HK/news/280902777.md) - [If You Invested $1000 In Deere Stock 10 Years Ago, You Would Have This Much Today](https://longbridge.com/zh-HK/news/281086779.md)